Use of botulinum toxin for the treatment of keloid scars: scoping review

▪ ABSTRACT

Introduction:

Visible scars can cause problems, whether aesthetic, psychological, functional, or social, mainly of great extension and volume, such as keloids. The discovery of new treatments for keloids is not easy, given the presence of some methodological and ethical obstacles, and it is an area that is little explored. Botulinum toxin has been presented as a therapeutic alternative in national and international studies, requiring a compilation and highlighting of the main studies that can support clinical practice. Thus, the objective was to present a scoping review on the therapeutic use of botulinum toxin for the treatment of keloid scars.

Method:

The review was carried out using the PICO strategy and using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. It was carried out in the PubMed/Medline, Virtual Health Library, and SciELO databases, considering studies from 2016 to September 2021.

Results:

Overall, 34 articles related to the topic were found. After filtering and selection, the review was constructed with the support of 5 articles. The studies varied between cohorts, case reports, randomized clinical trials, and case-control. It was possible to observe as main results of the short-term action of botulinum toxin in reducing keloids, greater effectiveness in reducing symptoms, and possibilities of clinical use for different populations and clinical manifestations.

Conclusion:

The mechanism of action of botulinum toxin can facilitate the treatment of keloids and reduce symptoms, requiring more robust studies to define effective scar management protocols.

Keywords:

Keloid - Therapeutic Human experimentation - Botulinum toxins, type A - Reconstructive surgical procedures - Evidence-based practice

Institution: Clínica Particular, João Pessoa, PB, Brazil.

Publikationsverlauf

Eingereicht: 10. Juli 2023

Angenommen: 04. Februar 2024

Artikel online veröffentlicht:
20. Mai 2025

• REFERÊNCIAS

• 1 Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. Int J Mol Sci 2017; 18 (03) 606
• 2 Cardoso AS, Teixeira DA, Oliveira BV, Carneiro PP, Junqueira RF. Botulinum toxin application in the secondary intention healing. Surg Cosmet Dermatol 2016; 8 (02) 163-166
• 3 Hochman B, Farkas CB, Isoldi FC, Ferrara SF, Furtado F, Ferreira LM. Distribuição de queloide e cicatriz hipertrófica segundo fototipos de pele de Fitzpatrick. Rev Bras Cir Plást 2012; 27 (02) 185-189
• 4 Gouveia BN, Ferreira LD, Rocha Sobrinho HM.. O uso da toxina botulínica em procedimentos estéticos. Rev Bras Mil Ciênc 2020; 6 (16) 56-63
• 5 Brasil. Ministério da Saúde. Biblioteca Virtual em Saúde. Queloide. 2021. Elaborado por: Sociedade Brasileira de Cirurgia Dermatológica e Sociedade Brasileira de Dermatologia. Brasília: Ministério da Saúde; 2021. [acesso 2021 Out 30]. Disponível em: https://bvsms.saude.gov.br/queloide/
• 6 Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review. J Cosmet Dermatol 2019; 18 (01) 10-15
• 7 Santos CMC, Pimenta CAM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Latino Am Enferm 2007; 15 (03) 508-511
• 8 Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D. et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018; 169 (07) 467-473
• 9 Pruksapong C, Yingtaweesittikul S, Burusapat C. Efficacy of Botulinum Toxin A in Preventing Recurrence Keloids: Double Blinded Randomized Controlled Trial Study: Intraindividual Subject. J Med Assoc Thai 2017; 100 (03) 280-286
• 10 Zhou M, Wang L, Jiang R, Zhu M, Chen F. Evaluation on efficacy and adverse reactions of combined therapy with botulinum toxin type A in treatment of keloid. J Jilin Un (Medicine Ed.) 2017; 6: 386-390
• 11 Rasaii S, Sohrabian N, Gianfaldoni S, Hadibarhaghtalab M, Pazyar N, Bakhshaeekia A. et al. Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study. Dermatol Ther 2019; 32 (02) e12781
• 12 Pires M, Soudo A, Costa MJ. Toxina Botulínica Tipo A no Tratamento das Cicatrizes Hipertróficas por Queimadura em Idade Pediátrica: Caso Clínico. Rev Soc Port Med Fís Reab 2020; 32 (03) 126-129
• 13 Motoki THC, Isoldi FC, Brito MJA, Filho AG, Ferreira LM. Keloid negatively affects body image. Burns 2019; 45 (03) 610-614
• 14 Dai X, Lei TC. Botulinum toxin A promotes the transdifferentiation of primary keloid myofibroblasts into adipocyte-like cells. Basic Clin Pharmacol Toxicol 2021; 129 (06) 462-469
• 15 Lee YI, Kim J, Yang CE, Hong JW, Lee WJ, Lee JH. Combined Therapeutic Strategies for Keloid Treatment. Dermatol Surg 2019; 45 (06) 802-810
• 16 Sohrabi C, Goutos I. The use of botulinum toxin in keloid scar management: a literature review. Scars Burn Heal 2020; 6: 2059513120926628